Chemistry:BTS 74,398
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H29Cl2N3OS |
| Molar mass | 418.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2][3] but was unsuccessful in human trials.[4]
References
- ↑ "Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors". The Journal of Pharmacology and Experimental Therapeutics 312 (3): 1124–31. March 2005. doi:10.1124/jpet.104.076554. PMID 15542624.
- ↑ "The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates". Movement Disorders 19 (1): 15–21. January 2004. doi:10.1002/mds.10596. PMID 14743355.
- ↑ "Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours". The European Journal of Neuroscience 21 (1): 179–86. January 2005. doi:10.1111/j.1460-9568.2004.03834.x. PMID 15654855.
- ↑ "Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398". Journal of Neural Transmission 115 (3): 423–9. 2008. doi:10.1007/s00702-007-0854-x. PMID 18250952.
 |  |
